Monday, June 27, 2016 9:15:05 AM
For some time now, MannKind has been dealing with incredibly high short interest, and that's a horrible thing. After all, short interest is a bet by investors that the stock is likely to fall in value, and, with short interest high, investor sentiment usually drags the value of a stock downward.
Nonetheless, short interest surrounding MNKD is starting to fall. In fact, according to a June publication by FINRA, the total short interest on the stock came to 86.48 million shares in the month. This brings the number down 11.05% from recent updates, when 97.22 million shares were sold short. The fact that short interest is declining is a great thing, as it shows that investor sentiment surrounding the stock is improving.
Recent News That Will Likely Increase Afrezza Sales
The reason that MNKD has had a rough time in the market over the past year or so is the fact that its flagship candidate, Afrezza, just isn't flying off of the shelves as investors thought it would. Nonetheless, the company released recent news that is overwhelmingly promising for Afrezza sales and for MannKind as a whole.
MNKD announced that it recently joined forces with JDRF, a foundation with a goal of funding research into the treatment and cure for type 1 diabetes. This collaboration is incredibly important, as the goal of the collaboration will be to advance new treatments and therapies as well as to use Afrezza as a primary treatment for the pediatric diabetic population. This will likely cause sales to climb in a big way over the long run, helping lead to big gains in MNKD stock. In a statement, Dr. Ray Urbanski, CMO at MannKind, had the following to offer with regard to the collaboration:
“We are excited to be working with JDRF and the leading scientific experts, community physicians, and people with diabetes that are associated with this organization... We have already begun to evaluate Afrezza for use in the pediatric population and we look forward to working with JDRF to advance our mutual interests in advancing therapies for all people with type 1 diabetes.”
What We Can Expect To See From MNKD Moving Forward
Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from MannKind. While the company has fallen on hard times as of late, investors are focused on Afrezza sales, and the new collaboration will likely lead to stronger sales volume. This will send the value of the stock upward in a big way. However, it's not the only reason I'm bullish.
Currently, MNKD is working to find new indications for technosphere, the technology that allows Afrezza to be inhaled. They announced a collaboration months ago that will look into treatments for several ailments. I'm expecting this to lead to strong profits in the long run as these treatments become available. All in all, MNKD may have a rough road ahead in the short run, but the long-run picture looks solid.
Recent MNKD News
- MannKind Announces CFO Transition • GlobeNewswire Inc. • 03/26/2024 08:05:00 PM
- INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps • GlobeNewswire Inc. • 03/11/2024 10:05:00 AM
- MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8 • GlobeNewswire Inc. • 03/05/2024 11:05:00 AM
- MannKind Corporation Announces Participation at Upcoming Conferences • GlobeNewswire Inc. • 03/04/2024 06:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:05:20 PM
- MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update • GlobeNewswire Inc. • 02/27/2024 09:00:00 PM
- MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024 • GlobeNewswire Inc. • 02/20/2024 11:00:00 AM
- MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza® • GlobeNewswire Inc. • 02/15/2024 11:05:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:00:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 11:06:28 AM
- MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million • GlobeNewswire Inc. • 01/02/2024 11:05:00 AM
- MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 12/28/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:15:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/16/2023 02:00:12 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/15/2023 09:09:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/15/2023 12:56:53 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/14/2023 09:08:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/07/2023 09:05:18 PM
- MannKind Corporation Reports 2023 Third Quarter Financial Results • GlobeNewswire Inc. • 11/07/2023 09:00:00 PM
- MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes • GlobeNewswire Inc. • 11/06/2023 11:15:00 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM